(October 30, 2018, 1:16 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on Oct. 29 affirmed that a pro se plaintiff’s withdrawal injury claim from the atypical antipsychotic Abilify is barred by a Texas’ rebuttable presumption about the adequacy of Food and Drug Administration-approved drug warnings (Peter B. Casey v. Bristol-Myers Squibb Company, et al., No. 18-50380, 5th Cir., 2018 U.S. App. LEXIS 30590)....